Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 348

The DOI matches its Crossref record.

Differential inhibition of fracture healing by non‐selective and cyclooxygenase‐2 selective non‐steroidal anti‐inflammatory drugs

Open access
Gerstenfeld, Louis C., Thiede, Mark, Seibert, Karen, Mielke, Cindy, Phippard, Deborah, Svagr, Bohus, Cullinane, Dennis, Einhorn, Thomas A.·2003·Journal of Orthopaedic Research

Abstract

Non‐steroidal anti‐inflammatory drugs (NSAIDs) specifically inhibit cyclooxygenase (COX) activity and are widely used as anti‐arthritics, post‐surgical analgesics, and for the relief of acute musculoskeletal pain. Recent studies suggest that non‐specific NSAIDs, which inhibit both COX‐1 and COX‐2 isoforms, delay bone healing. The objectives of this study were 2‐fold; first, to measure the relative changes in the normal expression of COX‐1 and COX‐2 mRNAs over a 42 day period of fracture healing and second, to compare the effects of a commonly used non‐specific NSAID, ketorolac, with a COX‐2 specific NSAID, Parecoxib (a pro‐drug of valdecoxib), on this process. Simple, closed, transverse fractures were generated in femora of male Sprague‐Dawley rats weighing approximately 450 g each. Total RNA was prepared from the calluses obtained prior to fracture and at 1, 3, 5, 7, 10, 14, 21, 35 and 42 days post‐fracture and levels of COX‐1 and COX‐2 mRNA were measured using real time PCR. While the relative levels of COX‐1 mRNA remained constant over a 21‐day period, COX‐2 mRNA levels showed peak expression during the first 14 days of healing and returned to basal levels by day 21. Mechanical properties of the calluses were then assessed at 21 and 35 days post‐fracture in untreated animals and animals treated with either ketorolac or high or low dose parecoxib. At both 21 and 35 days after fracture, calluses in the group treated with the ketorolac showed a significant reduction in mechanical strength and stiffness when compared with controls (p < 0.05). At the 21‐day time point, calluses of the parecoxib treated animals showed a lower mean mechanical strength than controls, but the inhibition was not statistically significant. Based on physical analysis of the bones, 3 of 12 (25%) of the ketorolac‐treated and 1 of 12 (8%) of the high dose parecoxib‐treated animals showed failure to unite their fractures by 21 days, while all fractures in both groups showed union by 35 days. Histological analysis at 21 days showed that the calluses in the ketorolac‐treated group contained substantial amounts of residual cartilage while neither the control nor the parecoxib‐treated animals showed comparable amounts of cartilage at this stage. These results demonstrate that ketorolac and parecoxib delay fracture healing in this model, but in this study daily administration of ketorolac, a non‐selective COX inhibitor had a greater affect on this process. They further demonstrate that a COX‐2 selective NSAID, such as parecoxib (valdecoxib), has only a small effect on delaying fracture healing even at doses that are known to fully inhibit prostaglandin production. © 2003 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0736-0266(03)00003-2

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 348

Metadata

Authors
Gerstenfeld, L. C., Thiede, M., Seibert, K., Mielke, C., Phippard, D., Svagr, B., Cullinane, D., & Einhorn, T. A.
Venue
Journal of Orthopaedic Research
Publisher
Wiley
Published
2003-07
Volume
21
Issue
4
Pages
670-675
ISSN
  • 0736-0266 (ISSN-L)
  • 1554-527X
OpenAlex
W2052192250
Cited by
348
References
0
FWCI
14.17
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential inhibition of fracture healing by non‐selective and cyclooxygenase‐2 selective non‐steroidal anti‐inflammatory drugs. https://app.cochat.ai/papers/10.1016/s0736-0266(03)00003-2
The paper
Gerstenfeld, L. C., Thiede, M., Seibert, K., Mielke, C., Phippard, D., Svagr, B., Cullinane, D., & Einhorn, T. A. (2003). Differential inhibition of fracture healing by non‐selective and cyclooxygenase‐2 selective non‐steroidal anti‐inflammatory drugs. Journal of Orthopaedic Research. https://doi.org/10.1016/s0736-0266(03)00003-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.